TY - JOUR
T1 - A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer
T2 - A southwest oncology group study
AU - Weick, James K.
AU - Crowley, John
AU - Natale, Ronald B.
AU - Hom, Ben Lin
AU - Rivkin, Saul
AU - Coltman, Charles A.
AU - Taylor, Sarah A.
AU - Livingston, Robert B.
PY - 1991
Y1 - 1991
N2 - Six hundred eighty assessable patients with measurable stage III M1 non-small-cell lung cancer (NSCLC) were randomized to one of five treatment arms including cisplatin, etoposide (VP-16) ± methylglyoxal bis-guanylhydrazone (MGBG; PVp, PVpM); cisplatin, vinblastine (PVe); or PVe alternating with vinblastine, mitomycin (PVeMi); or fluorouracil, vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP). The overall response rate was 20% with 3% complete responses and 17% partial remissions. The duration of these responses was not statistically different by treatment regimen and varied from 2.7 months to 5.0 months. The overall median survival for all patients was 5.3 months and is not different by treatment. Toxicity was greater in PVpM. The similarity of results for response, duration of response, and survival does not establish the superiority of any of these platinum-based regimens for standard clinical usage.
AB - Six hundred eighty assessable patients with measurable stage III M1 non-small-cell lung cancer (NSCLC) were randomized to one of five treatment arms including cisplatin, etoposide (VP-16) ± methylglyoxal bis-guanylhydrazone (MGBG; PVp, PVpM); cisplatin, vinblastine (PVe); or PVe alternating with vinblastine, mitomycin (PVeMi); or fluorouracil, vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP). The overall response rate was 20% with 3% complete responses and 17% partial remissions. The duration of these responses was not statistically different by treatment regimen and varied from 2.7 months to 5.0 months. The overall median survival for all patients was 5.3 months and is not different by treatment. Toxicity was greater in PVpM. The similarity of results for response, duration of response, and survival does not establish the superiority of any of these platinum-based regimens for standard clinical usage.
UR - http://www.scopus.com/inward/record.url?scp=0025735389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025735389&partnerID=8YFLogxK
U2 - 10.1200/JCO.1991.9.7.1157
DO - 10.1200/JCO.1991.9.7.1157
M3 - Article
C2 - 1646292
AN - SCOPUS:0025735389
SN - 0732-183X
VL - 9
SP - 1157
EP - 1162
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -